



Completion of Manufacturing

Brisbane, 9th of September 2016. Factor Therapeutics Limited (ASX : FTT) is pleased to announce the completion of manufacturing of its materials for its US-based Phase II clinical trial of VF-001 for the treatment of venous leg ulcers. This milestone marks the completion of a major scope of work that has involved transitioning operations to the US and manufacturing packaged drug product in conformance with the FDA's requirements for a biologic drug, at this stage of development.

The batch of materials (placebo, standard-dose, high-dose) are currently in the process of being released and the Investigational New Drug (IND) amendments are being finalized for publication and submission to the FDA, including a significantly revised and improved clinical protocol based on feedback from the Company's medical advisory board. This administrative process will take approximately two weeks to complete.

CEO, Nigel Johnson stated:

This is a significant milestone for the company and marks the completion of over two years of major effort and a major push in the US the past six months. We are grateful to shareholders for their patience.

Executive Director, Christian Behrenbruch stated:

In parallel to completing manufacturing, we have launched our clinical trial preparation including start-up activities with our CRO (Parexel), site qualification and preparation for patient recruitment. Despite earlier reported delays completing release assays, we are making excellent progress towards First-Patient-In for the Phase II study.

Corporate Contact

Dr. Christian P. Behrenbruch
Executive Director
Factor Therapeutics Limited
@: c.behrenbruch@factor-therapeutics.com

Investor Relations Contact

Kyahn Williamson
Head of Investor Communication
WE Buchan
@: kwilliamson@buchanwe.com.au

About Factor Therapeutics

Factor Therapeutics Limited ("Factor") is a biomedical technology company that is developing treatments for acute and chronic wound healing applications. Factor is a clinical stage company with its lead program (VF-001) in Phase II for the treatment of venous leg ulcers (VLUs). The company's platform technology originates from the Institute of Health and Biomedical Innovation at the Queensland University of Technology, Australia. Factor's shares are traded on the Australian Securities Exchange (ASX) under the ticker FTT. For more information, please visit www.factor-therapeutics.com.

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the "US Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available. This document may not be distributed or released in the United States.

Level 19,
179 Turbot Street
Brisbane QLD Australia 4000

phone +61 7 3334 3900
fax +61 7 3334 3999

GPO Box 1596
Brisbane QLD Australia 4001

www.factor-therapeutics.com